Pulse Biosciences Inc
PLSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.43B
Close$
$1.08
97.2% downside
Current Fair Value
97.2% downsideOvervalued by 97.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.43 Billion |
|---|---|
| Enterprise Value | $2.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 1.65 |
| Outstanding Shares | 67,788,877 |
Return
| Return on Equity | -112.47% |
|---|---|
| Return on Assets | -91.36% |
| Return on Invested Capital | -106.33% |
Valuation & Multiples
| P/E Ratio | -32.23 |
|---|---|
| PEG | -303.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7524.36 |
| Enterprise Value to EBIT | -31.04 |
| Enterprise Value to Net Income | -32 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$375,000
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1802▼ 48.18% |
|---|---|
| Total Calls | 67,700▲ 138.38% |
| Total Puts | 12,200▼ 35.11% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.46%▲ 2.07% |
|---|---|
| Total Invested | $167.60M▲ 92.87% |
| Investors Holding | 98▲ 16.00% |
ESG Score
No data
About Pulse Biosciences Inc
95 employeesPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive ad...